10 results about "Histamine Releases" patented technology

This invention belongs to the field of anti-allergy functional food technology, specifically relating to an anti-allergy composition containing inactivated Akkermansia myxophilus. Existing anti-allergy drugs have side effects. The composition of this invention contains inactivated Akkermansia myxophilus, quercetin, vitamin C, and zinc. This invention can improve allergic rhinitis, alleviate eczema symptoms, and improve allergic constitution by regulating immune balance and inhibiting histamine release. The composition of this invention is stable at room temperature and can be formulated into powder or chewable tablets.

The invention discloses an application of a nitrobenzene-containing urea compound in preparation of an anti-allergic reaction drug, and the nitrobenzene-containing urea compound can be applied in preparation of a drug for antagonizing mouse sole swelling and plasma exosmosis caused by C48 / 80. The invention also discloses application of the compound in preparation of drugs for antagonizing mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80. The nitrobenzene-containing urea compound can effectively relieve mouse sole swelling and plasma exosmosis, mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80, reduce serum histamine release and relieve body temperature decline, so that the occurrence of anaphylactoid reaction is inhibited, and the nitrobenzene-containing urea compound can be used for preventing and treating hyperplasia. Therefore, when the nitrobenzene-containing urea compound is used as an anti-drug anaphylaxis preparation, more possible treatment schemes are provided for clinical drug anaphylaxis treatment.

The invention discloses a method for reducing sensitization of beta-lactoglobulin and a hypoallergenic milk product, the hypoallergenic milk product is prepared through interaction reaction of beta-lactoglobulin and a natural anti-allergic active substance, and the natural anti-allergic active substance is myricetin. The method has the beneficial effects that the allergenicity of beta-Lg can be effectively reduced, a theoretical basis is provided for mechanism research of infant food allergy, and a data support is provided for development of functional infant food; the histamine release rate of KU812 and the expression quantity of IL-4, IL-6 and the like can be remarkably reduced, the food anaphylaxis is regulated and controlled on the gene expression level, and a feasible way is provided for achieving the anti-allergic effect to a certain degree.

The invention discloses a traditional Chinese medicine composition for relieving itching. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-50g of radix scutellariae, 6-50g of fructus gardeniae, 6-50g of fructus forsythiae, 6-50g of flos lonicerae and 6-50g of radix geutianae. According to the invention, the radix scutellariae for inhibiting histamine release, the fructus forsythiae for antagonizing histamine receptors and the felwort for blocking itching signal transduction are subjected to multi-way action to cover the whole link of itching-inducing medium generation-receptor combination-signal transmission, so that rapid itching relieving is realized; the cape jasmine for promoting prothrombin activation, the baical skullcap root for enhancing platelet aggregation and the honeysuckle flower for contracting blood vessels act together, so that the blood coagulation time is shortened, and the effect fluctuation of a single hemostasis mechanism is avoided; the five medicines jointly inhibit the release of inflammatory factors, enhance the local antibacterial ability, relieve inflammatory pruritus, prevent wound infection, avoid vicious circle of itching-grasping-infection-aggravated itching, and reduce the infection risk after bleeding.

The present invention provides methods of treating pathological conditions that cause hemolysis, brain edema, acute kidney injury, and anaphylactoid shock, alone or in combination with other agents, using at least one PLA2 inhibitor, the pathological conditions including poisoning, trauma, cerebral malaria, and mast cell diseases. The unexpected versatility, their dosage forms, and combinations of PLA2 inhibitors make them essential medicines for developing countries.

The invention discloses ulva agglutinin as well as an extraction method and application thereof. The extraction method comprises the following steps: S1, grinding dried ulva into ulva powder; s2, uniformly mixing the ulva powder with a NaCl-containing phosphate buffer solution, extracting ulva agglutinin by an ammonium sulfate precipitation method after ultrasonic-assisted extraction, so as to prepare an ulva agglutinin crude extract; and S3, purifying the ulva agglutinin crude extract by adopting an AKTA avat25 protein purification system, so as to obtain the ulva agglutinin. The ulva agglutinin has high sensitization, an RBL-2H3 cell model is established, and the sensitization of the ulva agglutinin is evaluated through the influence of the ulva agglutinin on the cell morphology or the cell histamine release rate. By combining ammonium sulfate precipitation with ion exchange chromatography, the purity of the ulva agglutinin is improved and is obviously superior to that in the prior art, and the method is more efficient and higher in purity.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The present invention provides a soothing botanical composition that inhibits histamine release, as well as a preparation method, application, and product, relating to the field of cosmetics technology. The botanical composition is composed of gentiana macrophylla, asafoetida, and small white apricot, with the mass ratio of gentiana macrophylla, asafoetida, and small white apricot being 1-5:1-5:3-9. By optimizing the ratio and preparation method of the two ingredients, the resulting composition exhibits synergistic effects in soothing, anti-allergic, and anti-inflammatory effects. By inhibiting histamine release and TRPV1 activation, the product significantly improves its soothing, anti-allergic, and anti-inflammatory effects.

The invention discloses a traditional Chinese medicine composition for treating mosquito bites, which realizes the following effects by accurately controlling the molecular collision energy (E is greater than or equal to 12kJ / mo) of active ingredients such as alkannin, hydroxysafflor yellow A and the like: inhibiting histamine release (IC50 is less than or equal to 15mu M); the itching relieving time is within 25 seconds; the pH value of the skin is kept in a physiological range of 6.8-7.2; the mast cell degranulation inhibition rate is greater than or equal to 75%.